Tran G, Zafar SY (2018) Financial toxicity and implications for cancer care in the era of molecular and immune therapies. Ann Transl Med 6(9):166
Article PubMed PubMed Central Google Scholar
Abrams HR, Durbin S, Huang CX, Johnson SF, Nayak RK, Zahner GJ, Peppercorn J (2021) Financial toxicity in cancer care: origins, impact, and solutions. Transl Behav Med 11(11):2043–2054
Ngan TT, Tien TH, Donnelly M, O’Neill C (2023) Financial toxicity among cancer patients, survivors and their families in the United Kingdom: a scoping review. J Public Health (Oxf) 45(4):e702-13
Carrera P, Yousuf Zafar S 2018 Financial toxicity. The MASCC textbook of cancer supportive care and survivorship 127–143
Hussaini SMQ, Gupta A, Dusetzina SB (2022) Financial toxicity of cancer treatment. JAMA Oncol 8(5):788
Pearce A, Tomalin B, Kaambwa B, Horevoorts N, Duijts S, Mols F, van de Poll-Franse L, Koczwara B (2019) Financial toxicity is more than costs of care: the relationship between employment and financial toxicity in long-term cancer survivors. J Cancer Surviv 13(1):10–20
Fenn KM, Evans SB, McCorkle R, DiGiovanna MP, Pusztai L, Sanft T, Hofstatter EW, Killelea BK, Knobf MT, Lannin DR et al (2014) Impact of financial burden of cancer on survivors’ quality of life. J Oncol Pract 10(5):332–338
Altice CK, Banegas MP, Tucker-Seeley RD, Yabroff KR (2016) Financial hardships experienced by cancer survivors: a systematic review. Journal of the National Cancer Institute 109(2):djw205
Article PubMed PubMed Central Google Scholar
Kale HP, Carroll NV (2016) Self-reported financial burden of cancer care and its effect on physical and mental health-related quality of life among US cancer survivors. Cancer 122(8):283–289
Lathan CS, Cronin A, Tucker-Seeley R, Zafar SY, Ayanian JZ, Schrag D (2016) Association of financial strain with symptom burden and quality of life for patients with lung or colorectal cancer. J Clin Oncol 34(15):1732–1740
Article CAS PubMed PubMed Central Google Scholar
Yousuf Zafar S (2016) Financial toxicity of cancer care: it’s time to intervene. J Natl Cancer Inst 108(5):djv370
Büttner M, Singer S, Hentschel L, Richter S, Hohenberger P, Kasper B, Andreou D, Pink D, Taylor K, Arndt K et al (2022) Financial toxicity in sarcoma patients and survivors in Germany: results from the multicenter PROSa study. Support Care Cancer 30(1):187–196
van der Graaf WTA, Tielen R, Bonenkamp JJ, Lemmens V, Verhoeven RHA, de Wilt JHW (2018) Nationwide trends in the incidence and outcome of patients with gastrointestinal stromal tumour in the imatinib era. Br J Surg 105(8):1020–1027
Joensuu H, Eriksson M, Sundby Hall K, Reichardt A, Hartmann JT, Pink D, Ramadori G, Hohenberger P, Al-Batran SE, Schlemmer M et al (2016) Adjuvant imatinib for high-risk GI stromal tumor: analysis of a randomized trial. J Clin Oncol 34(3):244–250
Article CAS PubMed Google Scholar
Mohammadi M, NS IJ, Hollander DD, Bleckman RF, Oosten AW, Desar IME, Reyners AKL, Steeghs N, Gelderblom H (2023) Improved efficacy of first-line imatinib in advanced gastrointestinal stromal tumors (GIST): the Dutch GIST registry data. Target Oncol 18(3):415–423
Article PubMed PubMed Central Google Scholar
van de Wal D, Fauske L, Bruland ØS, Jones RL, Kasper B, Wilson R, van der Graaf WTA, Husson O (2023) Psychological and social challenges of patients with locally advanced and metastatic gastrointestinal stromal tumours (GIST) on long-term treatment with tyrosine kinase inhibitors: a qualitative study with patients and medical oncologists. Support Care Cancer 31(6):352
Article PubMed PubMed Central Google Scholar
Carrera PM, Kantarjian HM, Blinder VS (2018) The financial burden and distress of patients with cancer: understanding and stepping-up action on the financial toxicity of cancer treatment. CA Cancer J Clin 68(2):153–165
Article PubMed PubMed Central Google Scholar
The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts. Blood 2013, 121(22):4439–4442
Thom B, Mamoor M, Lavery JA, Baxi SS, Khan N, Rogak LJ, Sidlow R, Korenstein D (2021) The experience of financial toxicity among advanced melanoma patients treated with immunotherapy. J Psychosoc Oncol 39(2):285–293
van de Poll-Franse LV, Horevoorts N, van Eenbergen M, Denollet J, Roukema JA, Aaronson NK, Vingerhoets A, Coebergh JW, de Vries J, Essink-Bot ML, Mols F (2011) The Patient Reported Outcomes Following Initial treatment and Long term Evaluation of Survivorship registry: scope, rationale and design of an infrastructure for the study of physical and psychosocial outcomes in cancer survivorship cohorts. Eur J Cancer 47(14):2188–2194
Kulis D, Bottomley A, Whittaker C, van de Poll-Franse LV, Darlington A, Holzner B, Koller M, Reijneveld JC, Tomaszewski K, Grønvold M (2017) PRM250 - the use of the Eortc Item Library to supplement eortc quality of life instruments. Value Health 20(9):A775
Piccinin C, Kuliś D, Bottomley A, Bjordal K, Coens C, Darlington A-S, Johnson C, Velikova G, Groenvold M, Group obotEQoL: EORTC Quality of Life Group Item Library user guidelines 2022(First Edition).
Tuomi K, Ilmarinen J, Jahkola A, Katajarinne L, Tulkki A: Work ability index, vol. 19: Finnish Institute of Occupational Health Helsinki; 1998.
Custers JA, van den Berg SW, van Laarhoven HW, Bleiker EM, Gielissen MF, Prins JB (2014) The Cancer Worry Scale: detecting fear of recurrence in breast cancer survivors. Cancer Nurs 37(1):E44-50
Douma KF, Aaronson NK, Vasen HF, Gerritsma MA, Gundy CM, Janssen EP, Vriends AH, Cats A, Verhoef S, Bleiker EM (2010) Psychological distress and use of psychosocial support in familial adenomatous polyposis. Psychooncology 19(3):289–298
Zigmond AS, Snaith RP (1983) The hospital anxiety and depression scale. Acta Psychiatr Scand 67(6):361–370
Article CAS PubMed Google Scholar
Olssøn I, Mykletun A, Dahl AA (2005) The hospital anxiety and depression rating scale: a cross-sectional study of psychometrics and case finding abilities in general practice. BMC Psychiatry 5(1):46
Article PubMed PubMed Central Google Scholar
Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, Filiberti A, Flechtner H, Fleishman SB, de Haes JC et al (1993) The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 85(5):365–376
Article CAS PubMed Google Scholar
de Ligt KM, Aaronson NK, Liegl G, Nolte S (2023) Updated normative data for the EORTC QLQ-C30 in the general Dutch population by age and sex: a cross-sectional panel research study. Qual Life Res 32(9):2477–2487
Article PubMed PubMed Central Google Scholar
Cocks K, King MT, Velikova G, Martyn St-James M, Fayers PM, Brown JM (2011) Evidence-based guidelines for determination of sample size and interpretation of the European Organisation for the Research and Treatment of Cancer Quality of Life Questionnaire Core 30. J Clin Oncol 29(1):89–96
Perrone F, Jommi C, Di Maio M, Gimigliano A, Gridelli C, Pignata S, Ciardiello F, Nuzzo F, de Matteis A, Del Mastro L et al (2016) The association of financial difficulties with clinical outcomes in cancer patients: secondary analysis of 16 academic prospective clinical trials conducted in Italy†. Ann Oncol 27(12):2224–2229
Article CAS PubMed Google Scholar
Fabian A, Domschikowski J, Greiner W, Bockelmann G, Karsten E, Rühle A, Nicolay NH, Grosu AL, Dunst J, Krug D (2022) Financial toxicity in cancer patients treated with radiotherapy in Germany-a cross-sectional study. Strahlenther Onkol 198(12):1053–1061
Article PubMed PubMed Central Google Scholar
Gordon LG, Merollini KMD, Lowe A, Chan RJ (2017) A systematic review of financial toxicity among cancer survivors: we can’t pay the co-pay. Patient 10(3):295–309
Kent EE, Forsythe LP, Yabroff KR, Weaver KE, de Moor JS, Rodriguez JL, Rowland JH (2013) Are survivors who report cancer-related financial problems more likely to forgo or delay medical care? Cancer 119(20):3710–3717
Lentz R, Benson AB III, Kircher S (2019) Financial toxicity in cancer care: prevalence, causes, consequences, and reduction strategies. J Surg Oncol 120(1):85–92
Smith GL, Lopez-Olivo MA, Advani PG, Ning MS, Geng Y, Giordano SH, Volk RJ (2019) Financial burdens of cancer treatment: a systematic review of risk factors and outcomes. J Natl Compr Canc Netw 17(10):1184–1192
Article PubMed PubMed Central Google Scholar
Koskinen J-P, Färkkilä N, Sintonen H, Saarto T, Taari K, Roine RP (2019) The association of financial difficulties and out-of-pocket payments with health-related quality of life among breast, prostate and colorectal cancer patients. Acta Oncol 58(7):1062–1068
Article CAS PubMed Google Scholar
Arastu A, Patel A, Mohile SG, Ciminelli J, Kaushik R, Wells M, Culakova E, Lei L, Xu H, Dougherty DW et al (2020) Assessment of financial toxicity among older adults with advanced cancer. JAMA Netw Open 3(12):e2025810–e2025810
Article PubMed PubMed Central Google Scholar
Chan K, Sepassi A, Saunders IM, Goodman A, Watanabe JH (2022) Effects of financial toxicity on prescription drug use and mental well-being in cancer patients. Explor Res Clin Soc Pharm 6:100136
PubMed PubMed Central Google Scholar
Custers JAE, Tielen R, Prins JB, de Wilt JHW, Gielissen MFM, van der Graaf WTA (2015) Fear of progression in patients with gastrointestinal stromal tumors (GIST): is extended lifetime related to the Sword of Damocles? Acta Oncol 54(8):1202–1208
留言 (0)